Biotron Limited (ASX:BIT)

Market Cap	2.65M
Revenue (ttm)	1.81M
Net Income (ttm)	-1.42M
Shares Out	1.33B
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	104,859
Average Volume	706,558
Open	0.0020
Previous Close	0.0020
Day's Range	0.0020 - 0.0020
52-Week Range	0.0020 - 0.0359
Beta	-0.70
RSI	41.57
Earnings Date	Aug 27, 2025

About Biotron

Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company’s lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of SARS-CoV-2, HIV-1, and hepatitis C virus infections. Biotron Limited was incorporated in 1999 and is based in Sydney, Australia.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 3
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: BIT

Financial Performance

In 2024, Biotron's revenue was 1.65 million, an increase of 14.94% compared to the previous year's 1.43 million. Losses were -3.44 million, -1.61% less than in 2023.